Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab + bendamustine versus bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma
2008-004177-17Phase 3Terminated
- Sponsor
- GSK
- Start
- Feb 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mature B-cell lymphoma comparing Ofatumumab + bendamustine with Bendamustine monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Feb 2010; status: terminated.
02
Drugs
ofatumumabbendamustine
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2008-004177-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004177-17.